# Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

> **NCT03155997** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 5637 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Standard Adjuvant Endocrine Therapy

## Key facts

- **NCT ID:** NCT03155997
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-12
- **Primary completion:** 2020-03-16
- **Final completion:** 2029-05
- **Target enrollment:** 5637 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03155997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03155997, "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03155997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*